- According to estimates from 7 analysts, Pyxis Oncology, Inc. stock's average price target has risen from $6.88 to $7.14, with forecasts ranging from $5 to $9 per share
- Based on the Jun. 30 closing price, the updated target implies approximately 137% potential upside
- Consensus rating remains at “Buy” across 8 covering analysts, with 7 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Pyxis Oncology, Inc. on the , and track all previous and future analyst recommendations for Pyxis Oncology, Inc. in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.